Genome-wide association studies (GWAS) have identified thousands of SNPs that are associated with human traits and diseases. But, because the vast majority of these SNPs are located in non-coding regions of the genome, the mechanisms by which they promote disease risk have remained elusive. Employing a new methodology that combines cistromics, epigenomics and genotype imputation, we annotate the non-coding regions of the genome in breast cancer cells and systematically identify the functional nature of SNPs associated with breast cancer risk. Our results show that breast cancer risk-associated SNPs are enriched in the cistromes of FOXA1 and ESR1 and the epigenome of histone H3 lysine 4 monomethylation (H3K4me1) in a cancer- and cell typespecific manner. Furthermore, the majority of the risk-associated SNPs modulate the affinity of chromatin for FOXA1 at distal regulatory elements, thereby resulting in allele-specific gene expression, which is exemplified by the effect of the rs4784227 SNP on the TOX3 gene within the 16q12.1 risk locus.
A r t i c l e s SNPs that associate with disease risk map predominantly to noncoding regions of the genome 1 . Over 70% of the risk-association loci in the National Human Genome Research Institute (NHGRI) GWAS catalog lack variants that map to exons within their haplotype block, indicating that they do not disrupt coding sequences 2 . A 'cistrome' has been defined as the complete set of binding sites for a transcription factor, assessed across the genome for a given cell type under a specific treatment. Similarly, an 'epigenome' is the complete set of DNA elements that carry the same epigenomic mark for a specific cell type and treatment. Cistromes and epigenomes, defined by chromatin immunoprecipitation combined with sequencing (ChIP-seq), identify the positions of regulatory elements and novel transcripts in both coding and non-coding regions across the whole genome [3] [4] [5] [6] [7] [8] . Notably, these approaches reveal that cistromes and epigenomes are cell type specific 4, 5, 9, 10 . For instance, the cistromes for the pioneer factor FOXA1 (also known as HNF3A) and the transcription factor ESR1 (estrogen receptor α; also known as ERα) have unique distributions in breast cancer cells compared to other cell types 4, [11] [12] [13] . Similarly, comparison of the epigenomes in diverse cell types of specific histone modifications found at regulatory elements, such as mono-or dimethylation of lysine 4 on histone H3 (H3K4me1 or H3K4me2), shows that functional regulatory elements are also lineage specific 4, 5 . The interplay between cistromes and epigenomes directs the transcriptional activity of the critical FOXA1 and ESR1 factors in breast cancer development to specific genomic regions, driving a unique gene expression profile 11, 12, 14 . Notably, differential recruitment of FOXA1 at enhancers drives cell type-specific transcriptional programs 4 . Because cistromes and epigenomes lie at the source of cell identity, we have investigated the functional relationship between breast cancer-associated SNPs and cistromes and epigenomes in breast cancer using a novel integrative functional genomics approach.
RESULTS

Risk-associated SNP enrichment
We first gathered the coordinates for the SNPs associated with breast cancer risk from the GWAS catalog available through the NHGRI (see URLs). Of these SNPs, only 1 in 44 mapped to coding exons, with 25 mapping to introns, 1 to a FOXA1-binding site and 3 to ESR1binding sites (Fig. 1a) . However, the number of SNPs assessed in GWAS genotyping microarrays provides low genomic coverage; less than 10% of all annotated SNPs (dbSNP Build 135) are covered by any given platform 15 . Statistically, it is therefore more likely for riskassociated SNPs to be in linkage disequilibrium (LD) with causal variants than to be causal themselves 16 . Therefore, we generated a list of all SNPs that were in strong LD with each breast cancerassociated SNP using data from the HapMap project ( Supplementary  Table 1 ). We used a highly stringent LD threshold of logarithm of odds (LOD) of >2 and D′ of 0.99. Through this imputation approach, we extended the coverage of risk-associated SNPs to include a more comprehensive list of putative functional SNPs that are in LD with these SNPs, thereby defining clusters that contain directly associated and linked SNPs (Fig. 1b) . We refer to the comprehensive collection of Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression 1 1 9 2 VOLUME 44 | NUMBER 11 | NOVEMBER 2012 Nature GeNetics A r t i c l e s all such clusters associated with a specific disease or trait, in this case, breast cancer, as its associated variant set (AVS). The breast cancer AVS is thus composed of 44 risk-associated SNPs and 1,315 linked SNPs (Supplementary Table 1) . The genome-wide distribution of the clusters containing these SNPs is reminiscent of the binding profiles of many transcription factors, such as FOXA1 and ESR1, as the clusters predominantly map to intronic and intergenic regions 4, 11, 12, 14 . By considering SNPs in LD with the risk-associated SNPs, the number of clusters mapping to coding exons increased from 1 to 5, and the number of clusters mapping to FOXA1-and ESR1-binding sites increased from 1 to 16 and 3 to 19, respectively ( Fig. 1c) . The significance of these mapping tallies was calculated through a novel computational method that we call variant set enrichment (VSE). VSE is a method based on permutation testing that generates null distributions from randomized variant sets while taking into account the heterogeneous LD structure of the breast cancer AVS ( Fig. 1d-g and Online Methods). This method is an extension of the work of Hindorff and colleagues 17 . By using VSE, we determined that the breast cancer AVS is not enriched in genes ( Fig. 1d,e ) but is strongly enriched for the FOXA1 and ESR1 cistromes ( Fig. 1f,g) .
We extended the VSE analysis to include a total of 72 cistromes from 16 different transcription factors and 27 epigenomes from 8 different histone modifications in breast cancer cells, including MCF7, T47D and ZR-75-1 cells (Fig. 2) . Samples were primarily treated with estradiol (E2), which was intended to stimulate the transcriptional activity of ESR1. Cistromes and epigenomes were either generated by our laboratory or were obtained from the literature and the Nuclear Receptor Cistrome project (see URLs). Only significant peaks (P < 1 × 10 −5 ) for cistromes and epigenomes were used in the analysis 4, 18 . Only enrichment scores satisfying a stringent Bonferroni-corrected threshold for significance (103 tests; P < 5.01 × 10 −4 ) are reported subsequently.
Among the 24 distinct breast cancer epigenomes and exon and intron annotations assessed, only H3K4me1-a histone modification that is associated with regulatory elements, mainly enhancersshowed enrichment (in samples untreated and treated with estrogen) ( Fig. 2a-c and Supplementary Tables 2 and 3) . Among the 72 distinct breast cancer cistromes, only the FOXA1 (three samples, untreated and treated) and ESR1 (one sample, treated) transcription factors showed enrichment (Fig. 2d,e and Supplementary Tables 4 and 5). H3K4me1 enrichment was independent of that for FOXA1-and ESR1-binding sites. After subtracting FOXA1-and ESR1-binding sites from the list of H3K4me1-modified elements, the epigenome for this mark remained significant (P = 2.94 × 10 −4 ) under estrogen treatment (Supplementary Table 6 ). Enrichment of FOXA1-and ESR1-binding sites and of H3K4me1-modified elements remained significant when using r 2 as a measure of LD instead of D′ and LOD for thresholds of r 2 of 0.8 or greater ( Supplementary Tables 7-9 ). These six enriched cistromes and epigenomes in breast cancer cells span 70% (31 of 44) of the clusters of risk-associated and linked SNPs for breast cancer ( Fig. 2a-e , dark heatmap rows). Five out of these six enrichment events were also significantly enriched with the breast cancer AVS when a null distribution based on DNase accessibility was used in a subsequent VSE run ( Supplementary Tables 10 and 11) .
VSE analysis of the breast cancer AVS across all cistromes and epigenomes in breast cancer cells showed that the enrichment for FOXA1 and ESR1 cistromes and the H3K4me1 epigenome was highly factor specific ( Fig. 2a-e ). However, because not all FOXA1 or ESR1 cistromes showed significant VSE scores, enrichment for the cistromes of the other transcription factors assayed in the study cannot be completely ruled out. Nuclear Receptor Cistrome project data sets are highly heterogeneous; the number of binding sites for FOXA1 in MCF7 cells varies over an order of magnitude depending on the laboratory in which data were generated. Given that we were intersecting 44 risk-associated SNPs with tens of thousands of binding sites, a tenfold decrease in the number of binding sites would be expected to markedly reduce our power to detect enrichment.
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None of these variant sets were enriched in their target cistromes or epigenomes in breast cancer cells, showing that the enrichment of the breast cancer AVS for these cistromes and epigenomes is specific to this cancer type ( Fig. 2g-i and Supplementary Tables 15-17) .
Conversely, the breast cancer AVS was tested for enrichment in prostate, bone and colon cell lines (LNCaP, VCaP, human metastatic cancer tissue, U2OS and Caco-2). Assessment of these cell lines for enriched transcription factor-binding sites and epigenetic modifications, including FOXA1, ESR2 and androgen receptor sites and H3K4me1 elements, respectively, did not show enrichment for the breast cancer AVS, showing that the enrichment of the breast cancer AVS is cell type specific ( Fig. 2f and Supplementary Table 18 ).
FOXA1 modulation
Having obtained these results, we then tested the ability of the clusters of breast cancer-associated and linked SNPs to disrupt the normal recruitment of FOXA1 to chromatin. We refer to the mechanism through which base-pair changes alter the recognition of a binding motif as affinity modulation. Using a novel computational method named intragenomic replicates (IGR), we are able to accurately predict affinity modulation by a SNP. The approach delineates the affinity of a given transcription factor for both the reference and variant alleles of a SNP while accounting for the genomic context around the SNP. The affinity of a transcription factor for a particular DNA sequence of length k (a k-mer) can be obtained by averaging binding data across a genomewide ChIP-seq data set for that transcription factor. We refer to this measurement as the affinity model for that k-mer. If a canonical binding motif is altered by a variant allele, the binding factor can find a higher affinity configuration by moving a few bases or reversing its orientation. IGR accounts for displacement effects by computing affinity models over a sliding window of k-mers around the SNP of interest (Fig. 3a) . Through this process, the collection of affinity models for increasing values of k are placed in a lattice structure that connects k-mers that are one base pair apart. Two lattices are constructed, one for each of the variant alleles (Fig. 3b) . The affinity models within each lattice are then filtered on the basis of their signal-to-noise ratios (Online Methods). The maxima among the remaining affinity models in the lattices are used to calculate the IGR score and P value (Fig. 3c) . This comparison between maxima represents the highest affinity for each allele given the genomic context of the SNP. We found that affinity model scores showed little correlation with position-weighted matrix (PWM) scores for the same set of 256 k-mers (Fig. 3d) . The models derived for a given transcription factor were consistent across laboratories and cell lines (Fig. 3e,f) . Because the chromatin landscape is a known barrier to the interaction between transcription factors and DNA, we restricted our k-mer search to chromatin regions that are favorable to binding 20 . When k-mer instances are not filtered on the basis of a favorable chromatin landscape, the affinity of the highly ranked k-mers is underestimated (Fig. 3g) .
Recruitment of FOXA1 is dependent on recognition of the forkhead (FKH) motif (Fig. 4a) . We explored the affinity landscape of the FKH motif by generating a collection of 30 10-mers, 1 for each possible variation at each of the 10 positions in the FKH motif ( Fig. 4b-d ). PWMs are useful in the identification of transcription factor-binding sites, but their scores correlate poorly with binding affinity (Fig. 4b,d,e ). The IGR method can accurately predict the affinity-modulating properties of the 30 10-mers ( Fig. 4c-e ). Furthermore, the physical association between a transcription factor and DNA cannot be fully captured by PWMs that consider each base of the motif in isolation. Changes at one side of the motif can aggravate or compensate for changes at the other side. We refer to this phenomenon as interaction effects between the bases of a motif. These effects can be marked, even reversing the affinity-modulating properties of an allele if the contextual sequence is ignored (Supplementary Fig. 1) .
The rs4784227 SNP is associated with breast cancer and is predicted to disrupt the binding of an undetermined transcription factor 21 . It is also a risk-associated SNP that directly maps to a FOXA1-binding site (Fig. 1a) . This SNP localizes to position 8 of the FKH motif that is recognized by FOXA1 (Fig. 4a) . The sequence surrounding this SNP differs from that encountered in the canonical FKH motif in that position 6 consists of G instead of A and the motif ends in GA instead of TT. The PWM for the FKH motif predicts a 9% affinity increase for the variant rs4784227[T] risk allele compared to the reference rs4784227[C] allele (6.24 versus 5.734, respectively; Fig. 4b) . Taking into account the interaction effects between motif positions, the IGR method predicts a 63% increase in affinity for the rs4784227[T] variant allele compared to the rs4784227[C] reference allele (fold change of 1.63, P < 1 × 10 −10 ; Fig. 4f and Supplementary Fig. 1) . Previous reports have shown allele-specific TCF4 recruitment at the riskassociated rs6983267 SNP in colon cancer cells [22] [23] [24] . IGR validates the affinity modulation by rs6983267 of TCF4 (fold change of 1.59, A r t i c l e s P < 1 × 10 −10 ; Fig. 4f ). Comparison of the IGR scores of the breast cancer risk-associated SNP rs4784227 assessed for TCF4 affinity and the colon cancer risk-associated SNP rs6983267 assessed for FOXA1 affinity showed that the affinity predictions are factor specific (fold changes of ~1, P > 0.05; Fig. 4f ).
Having probed a single risk-associated SNP, we then applied the IGR method to all risk-associated and linked SNP clusters and found that the breast cancer AVS is enriched in affinity-modulating SNPs for FOXA1 ( Supplementary Table 19 ). Of the 44 SNP clusters in the breast cancer AVS, 33 contained SNPs mapping to the FOXA1 cistrome or the H3K4me2 epigenome in breast cancer cells. These clusters harbored the regions where FOXA1-binding sites can be created or destroyed; these were the only clusters considered in this analysis 4 . For each cluster, we computed IGR scores for all SNPs in FOXA1-binding or H3K4me2-modified regions, thereby excluding linked SNPs lacking the ability to disrupt FOXA1 function in breast cancer cells, and tallied the number of affinity-modulating SNPs in each cluster. We then used the VSE method to generate a null distribution for the number of affinity-modulating variants in randomized sets of clusters. The significance threshold for affinity modulation was based on a Bonferroni correction that took into account all tests across all permutations (P < 1 × 10 −6 ). Out of the 33 clusters mapping to FOXA1-binding or H3K4me2-modified regions, 24 (73%) contained affinity-modulating SNPs (P = 0.009; Fig. 5a ). This finding signifies that more than half of all SNPs that are associated with breast cancer modulate the affinity of chromatin for FOXA1. Genotyping of the SNPs that were predicted to be disruptive of FOXA1 binding in 4 breast cancer cell lines (MCF7, BT474, T47D and ZR-75-1) identified 13 SNPs (including the rs4784227 variant) that were heterozygous in at least 1 cell line. Of these predicted SNPs, 77% (10 of 13) showed a significant and concordant allele-specific binding preference for FOXA1, as determined by in vivo allele-specific ChIP assays (Fig. 5b) . This comprehensive approach validates the power of IGR to identify affinity-modulating SNPs.
TOX3 disruption
To show in vivo that the disruptive SNPs that were identified through the VSE and IGR methods can promote breast cancer development, we initially focused on the breast cancer-associated SNP rs4784227, which is heterozygous in MCF7 breast cancer cells. This heterozygosity allowed us to determine the allele-specific function of a variant within its natural genomic context. The rs4784227 SNP directly overlaps an FKH motif in a FOXA1-binding site that lies in a regulatory element (that is subject to H3K4me2 modification) 18 kb away from the TOX3 gene (also known as TNRC9 and CAGF9; Fig. 6a,b) . The IGR method predicted that the rs4784227[T] variant allele would favor FOXA1 binding over the rs4784227[C] reference allele ( Fig. 4f and Supplementary  Fig. 1) . Accordingly, allele-specific directed ChIP assays in vivo confirmed that FOXA1 is preferentially recruited to the rs4784227[T] risk allele (Fig. 6b) . This change in affinity is independent from changes in H3K4me2 modification-the epigenetic signature favorable to FOXA1 binding-as H3K4me2 levels were equivalent for the two rs4784227 alleles in MCF7 breast cancer cells 4 (Fig. 6a) . Whereas FOXA1 commonly promotes gene expression, co-binding to chromatin with Groucho/TLE proteins leads to local chromatin condensation and transcriptional repression 25 . The variant rs4784227[T] risk allele associated with increased FOXA1 binding was also significantly bound by Groucho/TLE compared to the rs4784227[C] allele (Fig. 6c) . Furthermore, acetylation of histone H3 at lysine 9 (H3K9ac, a chromatin signature for active enhancers) was significantly less enriched at the rs4784227[T] allele versus the rs4784227[C] allele 7 (Fig. 6d) .
Chromatin conformation capture assays (3C) using BglII or MspI restriction enzyme digestion revealed that the region containing rs4784227 physically interacts with the promoter of the TOX3 gene (P < 0.04). Consequently, TOX3 is a gene target of the regulatory region harboring rs4784227. To assess the impact of the rs4784227 alleles on TOX3 gene expression, we identified a SNP (rs2193094) in the first intron of TOX3 that is heterozygous in MCF7 cells. Sequencing the 3C product revealed that the rs4784227[C] reference allele and the rs4784227[T] variant allele are physically linked to the rs2193094[T] and rs2193094[G] alleles, respectively (Fig. 6e,f and Supplementary  Fig. 2) . Allele-specific expression assays showed that the rs2193094[T] allele is preferentially expressed compared to the rs2193094[G] allele, suggesting that the rs4784227[T] variant allele has a repressive effect on TOX3 expression ( Fig. 6g) . This finding agrees with the results of previous in vitro luciferase reporter assays 21 .
RNA sequencing (RNA-seq) data from MCF7 cells revealed that six genes (TOX3, CHD9, RBL2, AKTIP, RPGRIP1L and FTO) are expressed from the ~3.5-Mb genomic window centered on the rs4784227 SNP (Supplementary Fig. 3) . In addition to the rs2193094 SNP within the first intron of TOX3, we identified heterozygous SNPs within the intronic regions of CHD9 and FTO (rs35925303 and rs11646260, respectively) by genotyping MCF7 cells. Whereas the rs2193094[G] variant allele was associated with a decrease in TOX3 RNA levels compared to the rs2193094[T] reference allele, no significant difference in RNA levels was detected for the variant and reference alleles rs35925303 (CHD9) or rs11646260 (FTO) (Fig. 7a) . Furthermore, we genotyped the rs4784227 SNP in 11 breast cancer cell lines expressing ESR1 and FOXA1 and extracted the expression data for TOX3 from the Neve breast cancer cell lines database 1 . Only one cell line, T47D, is homozygous for the rs4784227[T] allele. Correspondingly, T47D had the lowest expression of TOX3. Comparing all heterozygous (n = 3) cell lines with those that are homozygous for the rs4784227[C] allele (n = 7), we observed a significant association between the Fig. 7b ). This association agrees with a previous study that identified an association between the rs3803662 SNP and TOX3 gene expression in a study of 1,401 individuals of European ancestry with breast cancer 26 . rs3803662 is in significant LD with rs4784227 in individuals of European ancestry (r 2 = 0.864, D′ = 1; HapMap Utah residents of Northern and Western European ancestry (CEU)) ( Supplementary Table 20 ). In fact, rs4784227[T] only segregates with rs3803662[A], which is also associated with a decrease in TOX3 gene expression, supporting our conclusion that the functional rs4784227[T] allele is associated with a decrease in the expression of TOX3. In addition, we included the remaining five genes (CHD9, RBL2, AKTIP, RPGRIP1L and FTO) expressed from the ~3.5-Mb window centered on rs4784227 in expression quantitative trait locus (eQTL) assays ( Fig. 7b and Supplementary Fig. 3 ). rs4784227 was not significantly associated with the expression of these genes. Overall, these data suggest that allele-specific expression is unique to TOX3 at this locus and is dependent on the genotype at rs4784227. To assess the role of TOX3 in breast cancer cells, we performed a cell proliferation assay after silencing TOX3. We used the ZR-75-1 breast cancer cell line for this analysis because of its high expression of TOX3. Silencing of TOX3 in ZR-75-1 breast cancer cells significantly increased cell proliferation compared to the control treatment (small interfering RNA (siRNA) against luciferase), suggesting that TOX3 functions as a tumor suppressor in breast cancer cells ( Fig. 7c,d) .
DISCUSSION
The mechanisms underlying breast cancer risk-associated SNPs are unknown. As with most other complex traits, these risk-associated SNPs map to the non-coding regions of the genome 2 . Here, we show that breast cancer-associated SNPs are enriched for FOXA1 and ESR1 transcription factor-binding sites and H3K4me1 histone modification. Furthermore, we reveal that enrichment is dependent on factor, cell type and cancer type. The body of evidence supporting regulatory mechanisms for GWAS-identified risk-associated SNPs is steadily growing [27] [28] [29] [30] . Heterozygous sites with differential allelic occupancy within 100 bp of transcription start sites have been shown to have a strong association with differential gene expression and to be enriched for GWAS-identified SNPs 31 . Binding of the FOXA1 pioneer factor is central for chromatin opening and nucleosome positioning favorable to transcription factor recruitment 4, 11, 12, 32, 33 . In addition, FOXA1 is central to the establishment of the transcriptional programs that respond to estrogen stimulation in ESR1-positive breast cancer cells 4, 11, 12, 32, 34, 35 .
Among the elusive breast cancer-associated SNPs, rs4784227 is the most studied. The 16q12.1 locus, which harbors rs4784227 and the TOX3 gene, has been associated with breast cancer through GWAS in populations of European, Asian and African ancestry [36] [37] [38] [39] . Fine-scale mapping of the 16q12.1 locus has revealed that rs4784227 is the most strongly associated SNP in European and Asian populations 21, 40 . In in vitro experiments, the rs4784227[T] risk allele reduces luciferase reporter activity and alters DNA-protein binding patterns, suggesting a regulatory role for the rs4784227 SNP 21 . Functionally, TOX3 belongs to the high-mobility-group (HMG)-box family of proteins that modify chromatin structure 41 . It is expressed mainly in epithelial cells and targets both antiapoptotic and proapoptotic transcripts, protecting against cell death 42 . Furthermore, it stimulates estrogen-response element (ERE)-dependent transcriptional programs 42 . Statistically, TOX3 is differentially expressed in breast cancers that relapse to bone 43 . SNPs contained within the gene interact multiplicatively with mutations in BRCA1 or BRCA2, increasing breast cancer risk 44 . Here, we show that the rs4784227[T] risk allele produces a fivefold decrease in TOX3 gene expression. This reduction is due to an increase in affinity for FOXA1 at the enhancer where rs4784227 is located. FOXA1 binding is coupled to the recruitment of the TLE repressor, which diminishes the strength of the enhancer (through diminished H3K9ac modification). Mediated through a chromatin loop that interacts with the TOX3 promoter, the weakened rs4784227 enhancer downregulates the gene's transcriptional output (Fig. 8) . This mechanism of action for a cancer risk-associated SNP, that is, the disruption of transcription factor binding at a distal enhancer and the subsequent change in gene expression, such as reported in CRC, seems to be a common mechanism of action for risk-associated SNPs [22] [23] [24] .
There is a marked disparity between the number of SNPs associated with all cancers and the number of SNPs (rs6983267, rs4784227 and rs1859962) that have been functionally characterized 45, 46 . Therefore, it has been impossible to extrapolate the general mechanisms of genetic risk promotion for any particular disease. Here, we show that, for breast cancer, the majority of risk-associated SNPs modulate FOXA1 binding. First, they are in complete LD with SNPs localized to sites of FOXA1 binding, and, second, these linked SNPs are capable of changing the recruitment of FOXA1 in a significant manner. Pioneer factors, such as FOXA1, and lineage-specific factors, such as ESR1, underlie the transcriptional programs that establish cell identity 4 . Accordingly, we have shown that the majority of SNPs that can disrupt normal breast cell identity modulate the binding of the FOXA1 pioneer factor.
It is time to shift gears toward the post-GWAS phase of human genetics 47 . A set of principles has been proposed for the post-GWAS functional characterization of cancer risk loci 45 . But there is still one major hurdle to overcome before this transition can be made. The number of GWAS-identified risk-associated SNPs is large and growing, and each associated SNP has hundreds or thousands of linked SNPs. Furthermore, because the majority of linked SNPs lie in regulatory regions, each of these SNPs has an array of potential gene targets through multiple interactions mediated by chromatin loops. This branching morass makes the exhaustive functional characterization of all GWAS results unfeasible. A mechanism is required that can prioritize this overabundance of putative causal SNPs. The methods developed and applied in this study provide such a mechanism (Supplementary Fig. 4) . First, they determine the most promising npg transcription factors, histone modifications or other genomic annotations to interrogate (VSE). Second, they identify candidate SNPs among the thousands of linked SNPs for experimental follow-up studies (IGR). This integration of functional genomics data will allow the post-GWAS characterization of risk loci to gain traction and advance.
set of variants in affinity modulators. We first determine how many of the SNPs in the AVS map to transcription factor-binding sites or histone modifications favorable to binding. These represent the subset of linked SNPs contained in the regulatory regions where binding sites can be created or destroyed; we refer to these as regulatory SNPs. We then calculate the modulator quotient. The numerator of this quotient is the number of clusters of risk-associated and regulatory SNPs that have at least one significant affinity-modulating regulatory SNP. The denominator is the number of clusters of risk-associated and regulatory SNPs in the AVS. Risk-associated SNPs that do not contain regulatory SNPs are not considered in the modulator quotient. The modulator quotient null distribution over the set of MRVS is then used as in VSE to calculate a P value for the enrichment of the AVS in affinity-modulating SNPs.
Experimental procedures. Nucleosome-resolution ChIP-seq assays. MCF7 breast cancer cells were treated with MNase (Sigma, N3755), and ChIP assays were performed with antibody to H3K4me2 (Millipore, CMA303), as previously published 33 . Libraries were prepared for the Illumina Genome Analyzer according to the manufacturer's instructions. Regions that were significantly (P < 1 × 10 −5 ) enriched for H3K4me2 were detected using MACS software with default parameters 48 . H3K4me2 enrichment was validated by ChIP-qPCR.
In vivo allele-specific binding assays. ChIP assays were performed as previously described 4 . ChIP assays were performed using antibodies to FoxA1 (Abcam, ab5089), H3K4me2 (Millipore, 07-030), TLE (Santa Cruz Biotechnology, sc-13373X) and H3K9Ac (Abcam, ab4441). The allele-specific MAMA PCRbased genotyping technique was applied to assess differential ChIP enrichment on heterozygous alleles, as described previously 46, 49 .
3C-qPCR assays. Chromosome conformation capture (3C) technology coupled to qPCR was performed according to a published protocol 50 . Briefly, 5 × 10 6 MCF7 cells were subjected to formaldehyde cross-linking (1% formaldehyde, 10 min at room temperature) of interacting chromatin segments. This step was followed by BglII (or MspI, for higher resolution) digestion (400 U, overnight at 37 °C) and ligation (T4 DNA ligase, 4,000 U, 4 h at 16 °C). DNA fragments were cleaned by phenol-chloroform and ethanol extraction. qPCR was performed to quantify ligated DNA fragments. BAC clones were used to verify primer efficiency and to normalize the 3C interaction frequency.
In vivo allele-specific gene expression. A primer binding to a sequence outside of the rs2193094 SNP and its closest MspI restriction enzyme site and a primer binding to a sequence outside of the rs4784227 SNP and its closest MspI site were used to PCR amplify the MspI 3C product from MCF7 cells. PCR-amplified products were first cloned into an empty vector and were then sequenced using the Sanger sequencing approach, thereby revealing the linkage between the two alleles of the rs2193094 and rs4784227 SNPs. MCF7 genomic DNA was extracted using the Qiagen DNeasy Blood and Tissue kit. Total nuclear RNA from MCF7 cells was extracted using TRIzol (Invitrogen), and reverse transcription was performed to convert RNA into cDNA. Primers surrounding the rs2193094, rs35925303 and rs11646260 SNPs were used to generate cDNA and for PCR assays. Sanger sequencing was performed to measure the amount of DNA and RNA encoding each allele of the rs2193094, rs35925303 and rs11646260 SNPs.
Cell line-based eQTL assays. The rs4784227 SNP was genotyped in 11 ERαpositive and FOXA1-positive breast cancer cell lines (T47D, HCC1428, MCF7, MDA-MB-415, UACC-812, ZR-75-1, BT-474, BT-483, MDA-MB-175VII, 600MPE and ZR-75-30). Gene expression data for TOX3, AKTIP, CHD9, FTO, RBL2 and RPGRIP1 (generated using probes 214774_x_at, 218373_at, 212615_ at, 209702_at, 212331_at and 206608_at, respectively) in these cell lines were extracted from the Neve breast cancer cell lines database 51 . SNP genotype data were then correlated with the expression levels of each of these genes.
Cell proliferation assays after TOX3 silencing. TOX3 was silenced by siRNA duplexes. Two sets of siRNA against TOX3 were designed through Dharmacon ( Supplementary Table 21 ). siRNA against luciferase was used as a negative control. RNA was isolated from ZR-75-1 breast cancer cells using the RNeasy Mini kit (Qiagen) according to the manufacturer's recommendations. Quantitative RT-PCR was performed as previously described 4 to confirm the silencing effect of the siRNA against TOX3. TOX3 RNA levels were normalized to those of 28S ribosomal RNA and were then normalized by TOX3 RNA levels in cells that received negative control siRNA targeting luciferase. The number of ZR-75-1 breast cancer cells was counted 2 d after TOX3 silencing. ZR-75-1 cells that received siRNA targeting luciferase were considered to be a control.
